Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: Key prehospital and emergency room treatment strategies

European Journal of Emergency Medicine

Volumn 16, Issue 5, 2009, Pages 244-255

  Goldstein, Patrick ^g   Lapostolle, Frederic ^a   Steg, Gabriel ^b   Danchin, Nicolas ^c   Assez, Nathalie ^g   Montalescot, Gilles ^d   Charpentier, Sandrine ^f   Wiel, Eric ^g   Juliard, Jean Michel ^e  

^a AVICENNE HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f CHU PURPAN   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute coronary syndromes; Ambulance treatment; Antiplatelets; Emergency care; Myocardial infarction; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; PLACEBO; PRASUGREL; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; UROKINASE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AMBULANCE; BLEEDING; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; EMERGENCY CARE; EMERGENCY WARD; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MORTALITY; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; CATHETER ABLATION; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 70349089738     PISSN: 09699546     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEJ.0b013e328329794e     Document Type: Review

References (103)

1. Dracup K, Alonzo AA, Atkins JM, Bennett NM, Braslow A, Clark LT, et al. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program.Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med 1997; 126:645-651.
2. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-775.
3. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397-402.
4. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311-322.
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588-636. (Pubitemid 39036178)
6. Arntz HR, Bossaert L, Filippatos GS. European resuscitation council guidelines for resuscitation 2005. Section 5. Initial management of acute coronary syndromes. Resuscitation 2005; 67 (Suppl 1):S87-S96.
7. Van De Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28-66.
8. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360:825-829. (Pubitemid 35257945)
9. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006; 113:2398-2405.
10. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135-142.
11. Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 2007; 23:173-179.
12. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90:358-363.
13. Lowel H, Meisinger C, Heier M, Hormann A, Kuch B, Gostomzyk J, et al. [Sex specific trends of sudden cardiac death and acute myocardial infarction: results of the population-based KORA/MONICA-Augsburg register 1985-1998]. Dtsch Med Wochenschr 2002; 127:2311-2316.
14. Wallentin L. Reducing time to treatment in acute myocardial infarction. Eur J Emerg Med 2000; 7:217-227.
15. Kost GJ, Tran NK. Point-of-care testing and cardiac biomarkers: the standard of care and vision for chest pain centers. Cardiol Clin 2005; 23:467-490. vi.
16. Lapandry C, Laperche T, Lambert Y, Sauval P, Zurek M, Fosse S. [Pre-hospital management of acute coronary syndromes with ST elevation in the Ile-de-france region: the E-MUST registry]. Arch Mal Coeur Vaiss 2005; 98:1137-1142.
17. Steg PG, Cambou JP, Goldstein P, Durand E, Sauval P, Kadri Z, et al. Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registry. Heart 2006; 92:1378-1383.
18. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278:2093-2098. (Pubitemid 28016233)
19. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733-742.
20. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824-826.
21. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108:2851-2856.
22. Nallamothu BK, Antman EM, Bates ER. Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of timeto- treatment? Am J Cardiol 2004; 94:772-774.
23. Bassand JP, Danchin N, Filippatos G, Gitt A, Hamm C, Silber S, et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26:2733-2741.
24. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111:761-767.
25. Danchin N. Should intravenous thrombolysis keep a place in the treatment of acute ST-elevation myocardial infarction? Eur Heart J 2006; 27:1131-1133.
26. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114:2019-2025.
27. Stenestrand U, Lindback J, Wallentin L. Long-term outcome of primary percutaneous coronary intervention vs. prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006; 296:1749-1756.
28. Ferrier C, Belle L, Labarere J, Fourny M, Vanzetto G, Guenot O, et al. [Comparison of mortality according to the revascularisation strategies and the symptom-to-management delay in ST-segment elevation myocardial infarction]. Arch Mal Coeur Vaiss 2007; 100:13-19.
29. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: grampian region early anistreplase trial. GREAT Group. BMJ 1992; 305:548-553.
30. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. The European Myocardial Infarction Project Group. N Engl J Med 1993; 329:383-389.
31. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283:2686-2692.
32. Danchin N, Blanchard D, Steg PG, Sauval P, Hanania G, Goldstein P, et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004; 110:1909-1915.
33. Bjorklund E, Stenestrand U, Lindback J, Svensson L,Wallentin L, Lindahl B. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27:1146-1152.
34. Zimarino M, Sacchetta D, Renda G, De Caterina R. Facilitated PCI: rationale, current evidence, open questions, and future directions. J Cardiovasc Pharmacol 2008; 51:3-10.
35. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005; 293:979-986.
36. Abraham J, Gibson C, Pena G, Sanz R, AlMahameed A, Murphy S, et al. Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2. J Thromb Thrombolysis 2008; [Epub ahead of print]
37. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367:569-578.
38. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367:579-588.
39. Kiernan TJ, Ting HH, Gersh BJ. Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. Eur Heart J 2007; 28:1545-1553.
40. Ellis SG, Tendera M, De Belder MA, Van Boven AJ,Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358:2205-2217.
41. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371:559-568.
42. Danchin N, Belle L, Goldstein P, Blanchard D, Weber S, Mulak G, et al. Combined pre-hospital thrombolysis and high use of early PCI in STEMI patients is associated with mortality outcomes comparing favourably with those of primary PCI: data from the French FAST-MI registry. Eur Heart J 2007; 28:571-572.
43. Goldstein P, Wiel E, Assez N, Adriansen C, Alauze C, Vanite F. ACS, management during the pre hospital phase. Elsevier SFAR editors. Annals of the French national congress on anaesthesiology and intensive care. 2005; 515-527.
44. Collet JP, Cambou JP, Goldstein P, Belle L, Sauval P, De Labriole P, et al. Type of first medical contact and transfer organization rather than the number of medical contacts prior to admission affect survival of STEMI patients. Insight from the FAST-MI registry [abstract]. Eur Heart J 2007; 28 (abstract supplement):825.
45. Liem SS, Van Der Hoeven BL, Oemrawsingh PV, Bax JJ, Van Der Bom JG, Bosch J, et al. MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 2007; 153:14.e1-14.e11.
46. Welsh RC, Chang W, Goldstein P, Adgey J, Granger CB, Verheugt FW, et al. Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart 2005; 91:1400-1406.
47. Assz N, Rouyer F, Lapostolle F, Adriansen C, Wiel E, Goldstein P. Non STEMI patients; management in the emergency phase. Elsevier SFAR editors. Annals of the French national congress on anaesthesiology and intensive care. 2007; 547-549.
48. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345-2353.
49. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477-1488.
50. Franzosi MG, Santoro E, De Vita C, Geraci E, Lotto A, Maggioni AP, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators. Circulation 1998; 98:2659-2665.
51. Bell WR Jr. Evaluation of thrombolytic agents. Drugs 1997; 54 (Suppl 3): 11-16.
52. Ouriel K. Comparison of safety and efficacy of the various thrombolytic agents. Rev Cardiovasc Med 2002; 3 (Suppl 2):S17-S24.
53. Mueller HS, Roberts R, Teichman SL, Sobel BE. Thrombolytic therapy in acute myocardial infarction: part I. Med Clin North Am 1988; 72:197-226. (Pubitemid 18062206)
54. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41:1229-1245.
55. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95:351-356.
56. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998; 98:2805-2814.
57. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716-722.
58. Van De Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137:786-791.
59. Cannon CP. Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am J Cardiol 2000; 85:17C-22C.
60. Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001; 1:51-66.
61. Gibson CM, Marble SJ. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Clin Cardiol 2001; 24:577-584.
62. Van De Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22:2253-2261.
63. Guerra DR, Karha J, Gibson CM. Safety and efficacy of tenecteplase in acute myocardial infarction. Expert Opin Pharmacother 2003; 4:791-798.
64. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97:211-218.
65. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360.
66. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al.; American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care); Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group; Society of Chest Pain Centers. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 2005; 111:2699-2710.
67. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1598-1660.
68. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189.
69. Sabatine MS. Something old, something new: beta blockers and clopidogrel in acute myocardial infarction. Lancet 2005; 366:1587-1589.
70. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, et al. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 2006; 48:37-42.
71. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294:1224-1232.
72. Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, et al. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J 2008; 155:133-139.
73. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621.
74. Dogan A, Ozgul M, Ozaydin M, Aslan SM, Gedikli O, Altinbas A. Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy. Am Heart J 2005; 149:1037-1042.
75. Zeymer U, Gitt AK, Junger C, Heer T,Wienbergen H, Koeth O, et al. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006; 27:2661-2666.
76. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116:2923-2932.
77. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
78. Fesmire FM, Decker WW, Diercks DB, Ghaemmaghami CA, Nazarian D, Brady WJ, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2006; 48:270-301.
79. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276:811-815.
80. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36:110-114.
81. Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. Curr Opin Cardiol 2001; 16:384-389.
82. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112:3855-3867.
83. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 2007; 28:1066-1071.
84. Labeque JN, Jais C, Dubos O, Denard M, Berhouet M, Leroux L, et al. Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv 2006; 67:207-213.
85. Mehta SR, Granger CB, Eikelboom JW, Bassand JP,Wallentin L, Faxon DP, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50:1742-1751.
86. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519-1530.
87. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216.
88. Singh S, Molnar J, Arora R. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovasc Pharmacol Ther 2007; 12:283-291.
89. Stone GW,Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
90. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-613.
91. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-1914.
92. Lincoff AM, Califf RM, Van De Werf F, Willerson JT, White HD, Armstrong PW, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288:2130-2135.
93. Glatt B, Luycx-Bore A, Guyon P, Chevalier B, Jullien T, Royer T, et al. Pre-hospitalization treatment with Abciximab in the preparation of patients for primary angioplasty in the acute phase of myocardial infarct. Immediate and long-term (one month) results. Arch Mal Coeur Vaiss 1999; 92:1301-1308.
94. Arhan A, Ecollan P, Madonna-Py B, Kergueno J, Bennaceur M, Josse MO, et al. Assessment of early administration of abciximab in acute ST-segment elevation myocardial infarction in the emergency room. Presse Med 2006; 35:45-50.
95. Svensson L, Aasa M, Dellborg M, Gibson CM, Kirtane A, Herlitz J, et al. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. Am Heart J 2006; 151:798.e791-e797.
96. Montalescot G, Barragan P,Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895-1903. (Pubitemid 32553358)
97. Admiral Investigators. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005; 26:2520-2523.
98. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292:362-366.
99. Hamm CW, van t'Hof A, ten Berg JM, editors. ONgoing-Tirofiban in Myocardial Infarction Evaluation :ON-TIME 2 trial. 57th scientific session of American College of Cardiology; 2008 March 29th-April 1st; Chicago.
100. Bertrand ME, McFadden EP. Late is perhaps not y too late for primary PCI in acute myocardial infarction. Eur Heart J 2002; 23:1146-1148.
101. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Journal [serial on the Internet]. 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf
102. American College of Cardiology, American Heart Association Task Force on Practice Guidelines. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2008; 71:E1-E40.
103. SAMU de France, Socié té francophone de mé decine d'urgence, Socié té franç aise de cardiologie, editors. Prise en charge de l'infarctus du myocarde à la phase aiguë en dehors des services de cardiologie. Confé rence de consensus; 2006 November; Paris, France.